Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2017-03-02 Environmental & Social …
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Environmental & Social Information Classification · 99% confidence The document is a press release dated March 2, 2017, announcing the publication of a review/meta-analysis in the British Medical Journal Open Gastroenterology regarding the superiority of endomicroscopy (Cellvizio) in diagnosing stomach cancer. The text focuses on communicating positive clinical results and market potential, typical of an announcement intended for investors and the public. It is not a full financial report (10-K or IR), a transcript (CT), or a formal regulatory filing like a proxy statement. Since it is an announcement about positive clinical/research findings that impacts the company's value proposition, it aligns best with a general corporate announcement. Given the options, and since it is not explicitly an Earnings Release (ER) or a specific financial/governance document, it falls under the general category for corporate news releases. However, because it is a specific announcement of a publication that supports the company's technology, it is most accurately classified as a general Regulatory Filing (RNS) if no better fit exists, or potentially an Investor Presentation (IP) if it were a slide deck, but here it is a news release about external validation. Given the nature of the content (announcing positive external validation/publication), RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for non-standard corporate news releases that aren't earnings or management changes.
2017-03-02 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Capital/Financing Update Classification · 99% confidence The document is titled "MAUNA KEA TECHNOLOGIES ANNONCE LA MISE EN PLACE D'UN FINANCEMENT PAR EMPRUNT OBLIGATAIRE DE 7 M€" (Mauna Kea Technologies announces the establishment of a €7M bond financing). The content details the securing of €7.0 million in non-dilutive financing through two tranches of bonds from IPF Partners. This clearly relates to the company's fundraising and capital structure activities. Based on the provided definitions, the most appropriate category is 'Capital/Financing Update' (CAP). The document is a formal announcement detailing the terms of the debt issuance.
2017-02-08 French
Communicated under the obligation to provide permanent information / Other communications
Capital/Financing Update Classification · 99% confidence The document is titled with a clear announcement: "MAUNA KEA TECHNOLOGIES SECURES A €7.0 MILLION DEBT FINANCING". It details the terms of a debt financing agreement, including tranches, interest rates, and maturity dates. This content directly relates to the company's fundraising and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS), as it describes a specific financial transaction.
2017-02-08 English
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 99% confidence The document is a press release dated February 2, 2017, announcing the appointment of John Soto as Chief Operating Officer (COO). This type of announcement concerns a change in the company's senior management team. Based on the provided definitions, the category 'Board/Management Information (Code: MANG)' is the most appropriate fit, as it covers 'Announcement of changes in the company's board of directors or senior management.' The document is not a formal regulatory filing like a 10-K, an earnings release, or a proxy statement.
2017-02-02 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 99% confidence The document is a press release dated February 2, 2017, announcing the appointment of John Soto as the new Chief Operating Officer (COO). This involves a change in senior management personnel. According to the definitions, announcements of changes in the company's board of directors or senior management fall under the 'Board/Management Information' category, which corresponds to the code MANG.
2017-02-02 French
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LA SOCIETE DE BOURSE GILBERT DUPONT" (Semi-annual balance sheet of the liquidity contract with the stock brokerage firm Gilbert Dupont). It details the status of a liquidity contract (likely a market-making or share buyback agreement) as of December 31, 2016, comparing it to the previous semi-annual balance from June 30, 2016. This type of regular reporting on share transactions, especially those related to maintaining market liquidity or share repurchase programs, aligns most closely with the definition of 'Transaction in Own Shares' (POS), which covers share repurchase/issuance activities. While it is a periodic report, it is highly specific to share transactions rather than general financial results (ER/IR) or a full annual report (10-K). Given the context of a liquidity contract balance, POS is the most appropriate fit.
2017-01-02 French

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.